Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Explore linked clinical trials.4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not applicable | 2026-09-02 | NCT05559645 | |
| Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC | SCLC; SCLC, Extensive Stage | Recruiting | Phase 2 | 2026-02-27 | NCT07110103 | |
| A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2025-12-15 | NCT07182682 | |
| Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC | non-small cell lung carcinoma | Recruiting | Phase 2 | 2025-07-25 | NCT06864624 |